CHGCY News and Press, Chugai Pharmaceuticals Co. Ltd. ADR From 09/14/23

Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...

DocuSign Inc. (DOCU) is expected to report $0.11 for Q2 2024 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Concrete Pumping Holdings Inc. (BBCP) is expected to report $0.16 for Q3 2023 ...

Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q2 2023

2023-07-27 17:44:28 ET Chugai Pharmaceutical press release ( OTCPK:CHGCF ): 1H GAAP EPS of ¥95.23. Revenue of ¥579.66B (-2.7% Y/Y). For further details see: Chugai Pharmaceutical GAAP EPS of ¥95.23, revenue of ¥579.66B

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain PR Newswire The companies have entered a partnership agreement to develop new digital solutions for the objective assessment and management of pain associated wi...

Morgan Stanley says that global obesity sales in 2030 could reach $54B, driven by Eli Lilly ( NYSE: LLY ) and Novo Nordisk’s ( NVO ) ( OTCPK:NONOF ), while other large-cap pharma players closely watch their dominance amid emerging data from new biotechs. Obesi...

Chugai Pharmaceutical press release (OTCPK:CHGCF): Q1 GAAP EPS of ¥80.09. Revenue of ¥360.6B (+113.6% Y/Y). For further details see: Chugai Pharmaceutical reports Q1 results

The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation

AstraZeneca (NASDAQ:AZN) will pay $775M to Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) unit Chugai Pharmaceutical (OTCPK:CHGCF) to resolve all patent disputes related to rare disease drug Ultomiris. AstraZeneca had inherited the rare disease drug Ultomiris after acquiring Alexion Pharmaceuticals...

Roche (OTCQX:RHHBY) is closing a patent infringement suit against AstraZeneca (NASDAQ:AZN) related to the rare disease medicine Ultomiris, Fierce Pharma reported. AstraZeneca had inherited the rare disease drug Ultomiris after acquiring Alexion Pharmaceuticals. Roche’s C...